B
RLMD icon

Braidwell’s Relmada Therapeutics RLMD Stock Holding History

Braidwell’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,582,257
Closed -$7.64M – 97
2025
Q4 		$7.64M Buy
+1,582,257
New +$5.3M 0.24% 66

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Braidwell's RLMD Position: Q1 2026 in Review

Braidwell sold out of Relmada Therapeutics (RLMD) in Q1 2026, closing a stake of 1,582,257 shares — an estimated $7.64M sold.

Braidwell first reported a position in RLMD in Q4 2025 and held it in 1 quarter. The position peaked at $7.64M in Q4 2025. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Braidwell reported no remaining Relmada Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Braidwell sold 1,582,257 Relmada Therapeutics shares in Q1 2026, an estimated $7.64M.
  • Braidwell first reported a position in Relmada Therapeutics in Q4 2025 and held it in 1 quarter.
  • Braidwell's Relmada Therapeutics position peaked at $7.64M in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.